IO Biotech Q4 EPS $(0.40) Misses $(0.39) Estimate
Portfolio Pulse from Happy Mohamed
IO Biotech (NASDAQ:IOBT) reported a Q4 EPS loss of $(0.40), missing the consensus estimate of $(0.39) by 2.56%. However, this represents a 42.03% improvement over the $(0.69) loss per share from the same period last year.
March 05, 2024 | 9:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
IO Biotech reported a Q4 EPS loss of $(0.40), missing estimates but showing significant year-over-year improvement.
While IO Biotech missed the EPS estimate, the significant improvement from the previous year's loss indicates a positive trend in reducing losses. This mixed result could lead to neutral short-term market reaction as investors weigh the miss against the year-over-year improvement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100